No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
HUN240621P27000
- 3.40
- 0.000.00%
15min DelayClose Apr 25 10:11 ET
0.00High0.00Low
0.00Open3.40Pre Close0 Volume0 Open Interest27.00Strike Price0.00Turnover0.00%IV-3.10%PremiumJun 21, 2024Expiry Date4.11Intrinsic Value100Multiplier-4DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma6.73Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
News
North American Spray Foam Insulation Market 2024: Trends, Opportunities and Competitive Analysis 2018-2030 Featuring BASF, FFL Partners, Carlisle Companies, and Huntsman
Jordan Sgro Joins Huntsman Mental Health Foundation as Assistant Vice President of Operations
SALT LAKE CITY, June 20, 2024 /PRNewswire/ -- Huntsman Mental Health Foundation (HMHF) today announced the appointment of Jordan Sgro as Assistant Vice President of Operations. In this role Jordan wi
Despite Shrinking by US$197m in the Past Week, Huntsman (NYSE:HUN) Shareholders Are Still up 38% Over 5 Years
Global Structural Adhesives Market Forecast to 2029 With Henkel, Sika, 3M, DuPont, and Huntsman Dominating the $17 Billion Industry
Huntsman (HUN) Unveils New Innovation Center in Belgium
Huntsman Inaugurates New Innovation Center in Tienen, Belgium
TIENEN, Belgium, June 13, 2024 /PRNewswire/ -- Huntsman Corporation (NYSE: HUN) officially opened a new innovation center in Tienen, Belgium on June 13, 2024, strengthening its research and developme
Comments
Despite low growth, undervalued Huntsman shares might be a good investment. However, the company's financial health is also key to consider. Its future outlook is possibly not fully reflected yet, offering a potentially attractive opportunity.
Should You Investigate Huntsman Corporation (NYSE:HUN) At US$24.82?Huntsman's low P/S ratio is down to limited revenue growth predictions. Failure to increase its revenue might keep its share price low and possibly lower P/S levels.
Huntsman's stagnant business growth, marked by a declining ROCE and stable capital employed, dampens its investment appeal despite a robust 43% stock return over five years.
Gapping up
In reaction to earnings/guidance:
• $Bowlero(BOWL.US$ +3.4%
Other news:
• $Intellia Therapeutics(NTLA.US$ +10.8% (Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002)
• $Gogo Inc(GOGO.US$ +5% (Repurchases 1.5 million shares of common stock from BlackRock)
• $ADC Therapeutics(ADCT.US$ +2.9% (ADC Therapeutics and Swedish Orphan Biovitrum AB (BIOVF) confirms positive CHM...
In reaction to earnings/guidance:
• $Bowlero(BOWL.US$ +3.4%
Other news:
• $Intellia Therapeutics(NTLA.US$ +10.8% (Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002)
• $Gogo Inc(GOGO.US$ +5% (Repurchases 1.5 million shares of common stock from BlackRock)
• $ADC Therapeutics(ADCT.US$ +2.9% (ADC Therapeutics and Swedish Orphan Biovitrum AB (BIOVF) confirms positive CHM...
13
Gainers:
• $National Vision(EYE.US$ +13.8% (appointed to join S&P SmallCap 600)
• $Braze(BRZE.US$ +12.2% (In reaction to earnings/guidance)
• $Oracle(ORCL.US$ +11.7% (In reaction to earnings/guidance)
• $TeraWulf(WULF.US$ +7.5% (announced recent financing actions and near-term ramp of digital infrastructure)
• $Continental Resources(CLR.US$ +7.5% (announces receipt of "take private" proposal from Hamm Family of $70/share)
•...
• $National Vision(EYE.US$ +13.8% (appointed to join S&P SmallCap 600)
• $Braze(BRZE.US$ +12.2% (In reaction to earnings/guidance)
• $Oracle(ORCL.US$ +11.7% (In reaction to earnings/guidance)
• $TeraWulf(WULF.US$ +7.5% (announced recent financing actions and near-term ramp of digital infrastructure)
• $Continental Resources(CLR.US$ +7.5% (announces receipt of "take private" proposal from Hamm Family of $70/share)
•...
8
4
Read more